[FLDM] Fluidigm Corporation


Type of security: Stock

Sector: Capital Goods

Industry: Biotechnology: Laboratory Analytical Instruments

Market Capitalization: 282.85 M

Exchange: NASDAQ

The data is delayed by 15 minutes.


Price: 7.48 Change: 0.29 (4.03%)
Ext. hours: Change: 0 (0%)

chart FLDM

Refresh chart

Strongest Trends Summary For FLDM

FLDM is in the medium-term down -83% below S&P in 1 year.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart


Description: Fluidigm Corporation develops, manufactures, and sells microfluidic systems worldwide. It offers BioMark HD System that performs high-throughput and single-cell targeted gene expression analysis, single nucleotide polymorphism (SNP) genotyping, and digital polymerase chain reaction (PCR) using Fluidigm DELTAgene and SNPtype assays, other chemistries, and Fluidigm Dynamic Array and Digital Array integrated fluidic circuits (IFCs). The company also provides C1 Single-Cell Auto Prep System, which enables the isolation, processing, and profiling of individual cells for genomic analysis for applications comprising single-cell targeted gene expression, single-cell micro ribonucleic acid (RNA) analysis, single-cell messenger RNA analysis, and single-cell targeted DNA sequencing using the company?s C1 Single-Cell Auto Prep Array IFCs and C1 reagent kit. In addition, it offers EP1 System, which performs SNP genotyping using Fluidigm SNPtype assays or TagMan assays, as well as end-point digital PCR using TaqMan assays,

See how to gain 20% in 14 sec with TrendsInvesting

Fundamental Ratios
Shares Outstanding29.01 M EPS EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters -3.18% Sales Growth - Q/Q-20.19% P/E
P/E To EPS Growth P/S2.41 P/BV1.99 Price/Cash Per Share2.43
Price/Free Cash Flow-9.42 ROA-13.5% ROE-37.45% ROI-15.7%
Current Ratio6.23 Quick Ratio5.53 Long Term Debt/Equity1.5 Debt Ratio0.17
Gross Margin61.87% Operating Margin-41.94% Net Profit Margin-45.42% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities3.73 M Cash From Investing Activities10.07 M Cash From Operating Activities-9.8 M Gross Profit16.08 M
Net Profit-15.93 M Operating Profit-14 M Total Assets395.03 M Total Current Assets155.23 M
Total Current Liabilities24.9 M Total Debt195.51 M Total Liabilities252.58 M Total Revenue26.73 M
Technical Data
High 52 week14.36 Low 52 week4.15 Last close4.15 Last change-2.35%
RSI24.85 Average true range0.22 Beta1.19 Volume281.03 K
Simple moving average 20 days-12.59% Simple moving average 50 days-23.66% Simple moving average 200 days-58.64%
Performance Data
Performance Week-5.9% Performance Month-25.09% Performance Quart-63.27% Performance Half-68.63%
Performance Year-47.2% Performance Year-to-date-51.86% Volatility daily2.95% Volatility weekly6.59%
Volatility monthly13.5% Volatility yearly46.78% Relative Volume318.24% Average Volume829.32 K
New High New Low


2020-05-19 08:30:10 | University of Paris Researchers Utilize Fluidigm Mass Cytometry and Maxpar Direct Immune Profiling Assay to Identify Distinct Phenotype among Patients with Severe COVID-19

2020-05-13 16:02:10 | Fluidigm to Present at Upcoming Health Care Investor Conferences

2020-05-12 11:44:00 | Why Fluidigm Stock Is Soaring Again Today

2020-05-09 23:01:27 | Fluidigm FLDM Q1 2020 Earnings Call Transcript

2020-05-08 19:35:09 | Edited Transcript of FLDM earnings conference call or presentation 7-May-20 9:30pm GMT

2020-05-07 16:05:10 | Fluidigm Announces First Quarter 2020 Financial Results

2020-05-07 16:03:10 | Fluidigm Expands Accessibility of Mass Cytometry and Imaging Mass Cytometry Technology with New Therapeutic Insights Services

2020-05-07 11:30:03 | Is Fluidigm FLDM Outperforming Other Medical Stocks This Year?

2020-04-23 08:30:10 | OU Medicine, University of Oklahoma Health Sciences Center and Oklahoma Medical Research Foundation File for FDA Emergency Use Authorization for COVID-19 Detection Test Utilizing Fluidigm Technology

2020-04-20 16:06:46 | Fluidigm Announces Conference Call and Webcast of First Quarter 2020 Financial Results

2020-04-14 16:05:10 | Fluidigm Provides Update on COVID-19 Impact and Preliminary Revenue Estimate for First Quarter 2020

2020-04-08 09:44:01 | Snap Up These 5 Stocks With Rising P/E

2020-04-02 08:30:10 | Fluidigm CyTOF Technology Used to Evaluate Stem Cell Therapy as a Potential Treatment for COVID-19 Pneumonia

2020-03-16 08:30:10 | Consortium of Medical Schools Led by Mount Sinai Fast-Tracking COVID-19 Detection Test Utilizing Fluidigm Microfluidics Technology

2020-03-13 08:05:10 | The Independent Director of Fluidigm Corporation NASDAQ:FLDM, Nicolas Barthelemy, Just Bought 160% More Shares

2020-03-11 08:30:10 | Fluidigm and SIgN Establish the First Center of Excellence in Singapore to Advance Imaging Mass Cytometry

2020-03-10 08:30:10 | Fluidigm Introduces AccuLift Laser Capture Microdissection System to Advance Translational and Clinical Pathology Research

2020-03-03 08:00:10 | Fluidigm and Next Gen Diagnostics Enter into Agreement to Improve the Efficiency of Pathogen Sample Preparation for Microbial Whole Genome Sequencing

2020-02-26 08:30:10 | Fluidigm Completes Acquisition of InstruNor AS

2020-02-13 08:10:58 | Fluidigm Corporation Just Reported Earnings, And Analysts Cut Their Target Price

2020-02-12 16:05:10 | Fluidigm to Participate in Upcoming Investor Conferences

2020-02-12 07:46:27 | Edited Transcript of FLDM earnings conference call or presentation 10-Feb-20 10:00pm GMT

2020-02-10 18:35:11 | Fluidigm FLDM Reports Q4 Loss, Tops Revenue Estimates

2020-02-10 16:05:10 | Fluidigm Announces Fourth Quarter and Full Year 2019 Financial Results

2020-02-10 16:02:10 | Fluidigm Establishes Center of Excellence at NCI-Designated Comprehensive Cancer Center to Advance Imaging Mass Cytometry

2020-02-10 15:00:00 | Fluidigm Corp. to Host Earnings Call

2020-02-10 08:00:10 | Fluidigm CyTOF Technology Selected by Covance to Develop Highly Multiplexed Human Immune Profiling Services

2020-02-03 12:30:05 | Earnings Preview: Fluidigm FLDM Q4 Earnings Expected to Decline

2020-01-30 07:28:33 | Those Who Purchased Fluidigm NASDAQ:FLDM Shares Five Years Ago Have A 90% Loss To Show For It

2020-01-20 11:32:56 | Landmark Nature Publication Demonstrates the Power of the Fluidigm Hyperion Imaging System to Identify Novel Cellular Signatures That Correlate with Distinct Clinical Outcomes

2020-01-14 08:30:10 | Fluidigm Provides Preliminary Financial Results for Fourth Quarter and Fiscal Year 2019

2020-01-13 08:30:10 | MOgene Selects Fluidigm Advanta Assays and Juno System to Expand Its NGS Services Portfolio

2019-12-18 08:30:10 | The University of Michigan Protein Assembly Lab Selects Hyperion Imaging System for Research In Cancer Immunotherapy and Immune Phenotyping

2019-12-16 07:12:11 | Is Fluidigm NASDAQ:FLDM Using Debt In A Risky Way?

2019-12-12 08:30:10 | Fluidigm Named to Greater Toronto's Top Employers for 2020

2019-12-10 08:30:10 | Fluidigm Expands Maxpar Antibody Portfolio for High-Multiplex Tissue Imaging

2019-12-09 08:30:10 | Fluidigm Receives Life Science Industry Award for the Maxpar Direct Immune Profiling System

2019-12-08 16:22:54 | Hedge Funds Have Never Been This Bullish On Fluidigm Corporation FLDM

2019-11-20 11:21:13 | Fluidigm Corporation Announces Pricing of Private Offering of $50 Million of 5.25% Convertible Senior Notes

2019-11-20 06:36:03 | Fluidigm Corporation Announces Proposed Private Offering of $45 Million of Convertible Senior Notes

2019-11-13 16:05:00 | Fluidigm to Participate in the 31st Annual Piper Jaffray Healthcare Conference

2019-11-10 15:29:22 | Analysts See 2 Falling Knives Bouncing Back

2019-11-06 02:08:22 | Edited Transcript of FLDM earnings conference call or presentation 5-Nov-19 10:00pm GMT

2019-11-05 19:55:12 | Fluidigm FLDM Reports Q3 Loss, Misses Revenue Estimates

2019-11-05 16:05:00 | Fluidigm Announces Third Quarter 2019 Financial Results

2019-11-05 16:02:00 | Fluidigm Drives a New Standard in Human Immune Profiling

2019-11-01 08:17:33 | Estimating The Fair Value Of Fluidigm Corporation NASDAQ:FLDM

2019-10-29 10:33:02 | Fluidigm FLDM May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

2019-10-28 20:23:10 | Fluidigm Corporation FLDM Is Burning These Hedge Funds

2019-10-15 16:15:00 | Fluidigm Showcases RNA Sequencing Innovations Using Microfluidics Technology at the 2019 American Society of Human Genetics ASHG Meeting